Compositions and methods for the prevention and treatment of cancer
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/00
C07K-014/00
A61K-047/48
A61K-047/62
A61K-047/69
출원번호
US-0353602
(2016-11-16)
등록번호
US-10172955
(2019-01-08)
발명자
/ 주소
Santamaria, Pedro
출원인 / 주소
UTI Limited Partnership
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
45
초록▼
Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class
Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cells to levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells include cytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response against metastatic or non-metastatic cancerous, pre-cancerous, or neoplastic cells in vivo. The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.
대표청구항▼
1. A complex comprising: (a) a nanoparticle core having a diameter from about 1 nm to about 100 nm;(b) from 10 to 500 cancer or tumor-relevant antigen/CD1 protein complexes coupled to the nanoparticle core; and(c) a plurality of co-stimulatory molecule complexes coupled to the nanoparticle core;wher
1. A complex comprising: (a) a nanoparticle core having a diameter from about 1 nm to about 100 nm;(b) from 10 to 500 cancer or tumor-relevant antigen/CD1 protein complexes coupled to the nanoparticle core; and(c) a plurality of co-stimulatory molecule complexes coupled to the nanoparticle core;wherein the ratio of co-stimulatory molecule complexes to the cancer or tumor-relevant antigen/CD1 protein complexes is from about 0.1:1 to about 50:1. 2. The complex of claim 1, wherein the nanoparticle core has a biodegradable layer on the outer surface of the nanoparticle core and from 10 to 500 cancer or tumor-relevant antigen/CD1 protein complexes and the co-stimulatory molecule complexes of the plurality are coupled to the nanoparticle core or the biodegradable layer on the nanoparticle core. 3. The complex of claim 1 or 2, wherein the ratio of co-stimulatory molecule complexes to the cancer or tumor-relevant antigen/CD1 protein complexes is from about 1:1 to about 50:1. 4. The complex of claim 1 or 2, wherein the nanoparticle core has a diameter from about 1 nm to about 50 nm. 5. The complex of claim 1 or 2, wherein the nanoparticle core has a diameter from about 1 nm to about 30 nm. 6. The complex of claim 1 or 2, wherein the co-stimulatory molecule complexes coupled to the nanoparticle core are identical. 7. The complex of claim 1 or 2, wherein the tumor-relevant antigen is a cancerous tumor relevant antigen. 8. The complex of claim 7, wherein the antigen is a melanoma-relevant antigen or a lung cancer-relevant antigen. 9. The complex of claim 1 or 2, wherein a plurality of identical cancer or tumor-relevant antigen epitopes are contained in the cancer or tumor relevant antigen/MHC complexes. 10. The complex of claim 9, wherein the plurality of antigen epitopes are derived from a single antigen or a plurality of antigens. 11. The complex of claim 1 or 2, wherein the co-stimulatory molecule complexes of the plurality comprise a co-stimulatory molecule selected from the group of the CD28 receptor (CD80(B7.1), CD86(B7.2)), 4-IBBL, CD40, IL-15/IL15Rα, and ICOS. 12. The complex of claim 1 or 2, wherein the nanoparticle core comprises one or more of a metal, a metal oxide, a metal sulfide, a metal selenide, a magnetic material, a polymer, gold, iron, or iron oxide. 13. The complex of claim 12, wherein the nanoparticle core comprises one or more of gold, iron, or iron oxide. 14. The complex of claim 1 or 2, wherein the nanoparticle core is biocompatible and bioabsorbable. 15. The complex of claim 1, wherein the co-stimulatory molecule complexes of the plurality and/or the cancer or tumor-relevant antigen/CD1 protein complexes of the plurality are covalently coupled to the nanoparticle core or the biodegradable layer. 16. The complex of claim 2, wherein the co-stimulatory molecule complexes of the plurality and/or the cancer or tumor-relevant antigen/CD1 protein complexes of the plurality are covalently coupled to the biodegradable layer. 17. The complex of claim 1, wherein the co-stimulatory molecule complexes of the plurality and/or the cancer or tumor-relevant antigen/CD1 protein complexes of the plurality are covalently coupled to the nanoparticle core via a linker. 18. The complex of claim 2, wherein the co-stimulatory molecule complexes of the plurality and/or the cancer or tumor-relevant antigen/CD1 protein complexes of the plurality are covalently coupled to the biodegradable layer via a linker. 19. The complex of claim 17, wherein the linker comprises ethylene glycol. 20. The complex of claim 18, wherein the linker comprises ethylene glycol. 21. The complex of claim 2, wherein the biodegradable layer on the nanoparticle core comprises dextran, mannitol, and/or poly(ethylene glycol). 22. The complex of claim 1, wherein the co-stimulatory molecule complexes of the plurality and/or the cancer or tumor-relevant antigen/CD1 protein complexes of the plurality are coupled to the nanoparticle core, each via one or more of a dimer, a trimer, and/or a dimer of a trimer. 23. The complex of claim 2, wherein the co-stimulatory molecule complexes of the plurality and/or the cancer or tumor-relevant antigen/CD1 protein complexes of the plurality are coupled to the nanoparticle core or the biodegradable layer on the nanoparticle core, each via one or more of a dimer, a trimer, and/or a dimer of a trimer. 24. A pharmaceutical composition comprising a plurality of complexes of claim 1 or 2. 25. The pharmaceutical composition of claim 24, further comprising a carrier.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (45)
Blattler Walter A. (Brookline MA) Lambert John M. (Brookline MA) Senter Peter D. (Jamaica Plain MA), Acid-cleavable compound, use in protein conjugates and drug delivery systems.
Hershberg,Robert M.; Hosken,Nancy Ann; Lodes,Michael J.; Mohamath,Raodoh, Compositions and methods for the therapy and diagnosis of inflammatory bowel disease.
Yatvin Milton B. (Portland OR) Stowell Michael H. B. (Pasadena CA) Gallicchio Vincent S. (Lexington KY) Meredith Michael J. (Lake Oswego OR), Covalent microparticle-drug conjugates for biological targeting.
Braun,Jonathan; Cohavy,Offer, Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens.
Gordon Julian (Arlesheim CHX) Staehelin Theophil (Arlesheim CHX) Towbin Harry (Allschwil CHX), Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays.
Konigsberg Paula J. (Pasadena CA) Richer Leroy L. (San Gabriel CA) Schmidt Paul G. (San Marino CA) Uliana Joseph A. (Sierra Madres CA), Liposome targeting using receptor specific ligands.
Tetelman Bruce (Fort Lee NJ) Milios Yannis (New York NY) Park Il-Pyung (Palisades Park NJ) Recht Tom (Forest Hills NY), Point-of-sale terminal for laundry or dry cleaning establishments.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Platzek Johannes (Berlin DEX) Niedballa Ulrich (Berlin DEX) Radeuchel Bernd (Berlin DEX), Process for the production of DTPA-tetraesters of terminal carboxylic acids.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.